Testing three medications together for hard-to-treat childhood leukemia

Plain-English translation of NCT06177067 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This study is testing whether combining three medications—, , and —can help children and young adults whose acute myeloid leukemia (a blood cancer) has come back or stopped responding to standard treatment. The research team will carefully increase the doses of the medication to find the safest and most effective combination. Participants will receive the treatment along with additional supportive care.

Many children and young adults with leukemia that returns or doesn't respond to initial chemotherapy have very limited options and poor survival rates. This trial is exploring whether this new combination of medications—which target the leukemia cells in different ways—might offer hope when other treatments have not worked.

Do you qualify?

You likely qualify if…

you are between 1 and 30 years old
you have been diagnosed with acute myeloid leukemia that has either come back after remission or did not respond to at least two rounds of chemotherapy
your bone marrow or blood shows specific genetic changes that the study is targeting
your heart, liver, and kidneys are functioning at acceptable levels
you are healthy enough to manage the treatment, as measured by standard performance scales
at least 14 days have passed since your last cancer treatment, and any side effects from that treatment have mostly resolved

You likely don't qualify if…

you are pregnant or breastfeeding
you have a very high number of leukemia cells in your blood (over 25,000 cells per microliter) that cannot be controlled with low-dose therapy
you have had a stem cell transplant in the past 60 days or are still taking certain rejection-prevention medications
you have active graft-versus-host disease (a complication from a prior transplant)

What participation looks like

You would receive the three medications, likely through injections or infusions, according to a treatment schedule determined by your doctors. The doses may be adjusted based on how your body responds and any side effects you experience. You will have regular clinic visits for blood tests, heart monitoring, and physical exams to track how well the treatment is working. If you respond well, you may continue treatment as long as it remains beneficial and you are tolerating it well, or you may transition to a stem cell transplant if that becomes an option.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Testing three medications together for hard-to-treat childhood leukemia

What is this trial?

Do you qualify?

What participation looks like

Trial locations(10 sites)